Vivos Therapeutics, Inc.2024财年第二财季实现净利润-1.93百万美元，同比增加65.10%

自选股智能写手08-19

8月19日，Vivos Therapeutics, Inc.（VVOS.US）公布财报，公告显示公司2024财年第二财季净利润为-1.93百万美元，同比增加65.10%；其中营业收入为4.05百万美元，同比增加19.12%，每股基本收益为-0.60美元。从资产负债表来看，Vivos Therapeutics, Inc.（VVOS.US）总负债9.50百万美元，其中短期债务484000.00美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460172967?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-19 00:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460172967","market":"us","top_or_hot":-1,"title":"Vivos Therapeutics, Inc.2024财年第二财季实现净利润-1.93百万美元，同比增加65.10%","media":"自选股智能写手","content":"<div>\n<p>8月19日，Vivos Therapeutics, Inc.（VVOS.US）公布财报，公告显示公司2024财年第二财季净利润为-1.93百万美元，同比增加65.10%；其中营业收入为4.05百万美元，同比增加19.12%，每股基本收益为-0.60美元。从资产负债表来看，Vivos Therapeutics, Inc.（VVOS.US）总负债9.50百万美元，其中短期债务484000.00美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081900032395a385c1&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivos Therapeutics, Inc.2024财年第二财季实现净利润-1.93百万美元，同比增加65.10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivos Therapeutics, Inc.2024财年第二财季实现净利润-1.93百万美元，同比增加65.10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-19 00:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081900032395a385c1&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月19日，Vivos Therapeutics, Inc.（VVOS.US）公布财报，公告显示公司2024财年第二财季净利润为-1.93百万美元，同比增加65.10%；其中营业收入为4.05百万美元，同比增加19.12%，每股基本收益为-0.60美元。从资产负债表来看，Vivos Therapeutics, Inc.（VVOS.US）总负债9.50百万美元，其中短期债务484000.00美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081900032395a385c1&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VVOS","symbol_name":"Vivos Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081900032395a385c1&s=b","article_id":"2460172967","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081900032395a385c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460172967","pubTimestamp":1723996984,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月19日，Vivos Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-1.93百万美元，同比增加65.10%；其中营业收入为4.05百万美元，同比增加19.12%，每股基本收益为-0.60美元。机构评级：截至2024年8月19日，当前有1家机构对Vivos Therapeutics, Inc.目标价做出预测，其中目标均价为6.40美元，其中最低目标价为6.40美元，最高目标价为6.40美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"VVOS":"Vivos Therapeutics","LENZ":"Therapeutics"},"translate_title":"Vivos Therapeutics, Inc. achieved net profit of-US $1.93 million in the second fiscal quarter of fiscal 2024, a year-on-year increase of 65.10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"VVOS":1},"content_text":"8月19日，Vivos Therapeutics, Inc.（VVOS.US）公布财报，公告显示公司2024财年第二财季净利润为-1.93百万美元，同比增加65.10%；其中营业收入为4.05百万美元，同比增加19.12%，每股基本收益为-0.60美元。从资产负债表来看，Vivos Therapeutics, Inc.（VVOS.US）总负债9.50百万美元，其中短期债务484000.00美元，资产负债比为1.67，流动比率为1.19。机构评级：截至2024年8月19日，当前有1家机构对Vivos Therapeutics, Inc.目标价做出预测，其中目标均价为6.40美元，其中最低目标价为6.40美元，最高目标价为6.40美元。公司简介：Vivos Therapeutics Inc 是一家医疗技术公司。该公司致力于开发和商业化为睡眠呼吸障碍（SDB）患者，包括轻度至中度阻塞性睡眠呼吸暂停（OSA）的患者，提供非手术，非侵入性，非药物和低成本的技术。 该公司为轻度至中度阻塞性睡眠呼吸暂停（OSA）的患者提供治疗，涉及定制口腔矫治器和称为 Vivos 系统的方案。Vivos 系统是一种治疗方案，通常结合使用定制的口腔矫治器规格和本公司开发的专有临床治疗方法，并由经过专门培训的牙医与医疗同行合作开具处方。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460172967"}